adx-102
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02402309)
Timeline
Indications
Mechanism of action
- reactive aldehydeINHIBITOR
reactive aldehyde inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- adx-102
- adx-102
- ns2
- ns2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03445650 | Phase 3 | Jul 19, 2018 | Aldeyra Therapeutics, Inc. |
| NCT03162783 | Phase 2 | Jun 1, 2017 | Aldeyra Therapeutics, Inc. |
| NCT03131154 | Phase 3 | Apr 26, 2017 | Aldeyra Therapeutics, Inc. |
| NCT03012165 | Phase 2 | Dec 1, 2016 | Aldeyra Therapeutics, Inc., ORA, Inc. |
| NCT02402309 | Phase 2 | Mar 1, 2015 | Aldeyra Therapeutics, Inc., University of Nebraska |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aldeyra Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2015 |
| ORA, Inc. | For profit | 1 | 0 | 1 | 2016 |
| University of Nebraska | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1